News Sentiment

VKTX sentiment intelligence

Viking Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 37.08 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.6% over one week, +22.1% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -4.6% Price reacting lower
Trend fit Trend active 22.1% over four weeks
Fair value -0.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 27
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Simply Wall Street 6
TradingView 6
Stocktwits 4
Quartr 4
simplywall.st 3
Stock Titan 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 14
Guidance 3
Analyst action 2
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Market source Direct company coverage

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Viking Therapeutics, Inc. (NASDAQ: VKTX) announced it will release its second-quarter 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and provide

Tone
Neutral 50/100
Event
Earnings
Published
22 Jul 2026 20:10
Source
Market source
Stock Titan Direct company coverage

Viking Therapeutics’ Q2 results arrive after markets close

Viking Therapeutics (NASDAQ: VKTX) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide corporate

Tone
Negative 41/100
Event
Earnings
Published
22 Jul 2026 20:10
Source
Stock Titan
PR Newswire Direct company coverage

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free and no-obliga

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 20:40
Source
PR Newswire
The Globe and Mail Direct company coverage

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on pipeline updates, particularly for its lead candidate VK2735 for obesity treatment. The company has no marketed drugs, so no revenues are expected, and analysts forecast

Tone
Negative 39/100
Event
Earnings
Published
18 Jul 2026 01:10
Source
The Globe and Mail
Market source Direct company coverage

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note

Viking Therapeutics (VKTX) stock performed strongly, gaining 1.95% while the broader market indices like the S&P 500, Dow, and Nasdaq fell. The company's stock has risen 19.72% over the past month, outperforming its sector and the S&P 500. Analysts expect Viking Therapeutics to r

Tone
Positive 63/100
Event
Market update
Published
17 Jul 2026 22:09
Source
Market source
Simply Wall Street Direct company coverage

Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial

Viking Therapeutics (VKTX) has initiated a Phase 1 study for VK3019, a potential weight loss therapy. Despite recent stock fluctuations, the company shows strong long-term momentum, with Simply Wall St's analysis suggesting it is 61% undervalued compared to a fair value of $92.72

Tone
Positive 61/100
Event
Market update
Published
17 Jul 2026 20:09
Source
Simply Wall Street
Pluang Direct company coverage

Law firm probes Viking Therapeutics officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties through potential self-dealing, which could result in shareholder damages. The firm is encouraging long-term shareholders to contact them for free consulta

Tone
Negative 20/100
Event
Market update
Published
17 Jul 2026 01:40
Source
Pluang
Stocktwits Direct company coverage

A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival

Viking Therapeutics' new obesity drug candidate, VK3019, demonstrated stronger early weight-loss signals in animal studies compared to Novo Nordisk's amylin therapy, although VKTX stock dipped slightly after the announcement. The company plans to begin Phase 1 testing for VK3019

Tone
Positive 63/100
Event
Market update
Published
11 Jul 2026 04:43
Source
Stocktwits
Yahoo! Finance Canada Direct company coverage

Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

Viking Therapeutics (VKTX) stock fell 5.54% in the latest trading session, underperforming the broader market which saw gains. Despite this dip, the company's shares have increased significantly over the last month. Investors are anticipating VKTX's upcoming financial results, wi

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 21:40
Source
Yahoo! Finance Canada
Benzinga Direct company coverage

Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years

Viking Therapeutics (NASDAQ: VKTX) has significantly outperformed the market over the last decade, with an annualized return of 40.15%. An initial investment of $1000 in VKTX stock ten years ago would now be worth $29,903.10. This impressive performance highlights the power of co

Tone
Positive 80/100
Event
Market update
Published
10 Jul 2026 16:39
Source
Benzinga
FXEmpire Direct company coverage

Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength

Viking Therapeutics (VKTX) is showing signs of a long-term bottoming pattern, with improving technical indicators suggesting a potential breakout. Key resistance is at $43.15, and recent advances with increased volume signal strengthening demand. While a pullback could precede a

Tone
Positive 71/100
Event
Guidance
Published
09 Jul 2026 21:33
Source
FXEmpire
Simply Wall Street Direct company coverage

Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?

Viking Therapeutics has expanded its obesity drug pipeline by initiating a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, alongside its existing GLP-1/GIP program. While VK3019 broadens the company's multi-mechanism approach to obesity treatment, the nea

Tone
Positive 63/100
Event
Market update
Published
09 Jul 2026 21:03
Source
Simply Wall Street
TradingView Direct company coverage

Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?

Viking Therapeutics (VKTX) is increasingly seen as a potential acquisition target due to its expanding obesity franchise, particularly with its lead candidate VK2735 and the addition of VK3019. The company is poised for a significant catalyst with upcoming data readouts from a ma

Tone
Positive 70/100
Event
Deals and strategy
Published
09 Jul 2026 14:03
Source
TradingView
Quartr Direct company coverage

Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference 2026 Summary

This summary from the Jefferies Global Healthcare Conference 2026 details Viking Therapeutics' progress, including two Phase III trials for obesity (VANQUISH-1 and VANQUISH-2) nearing data release in late 2027, and the impending launch of two Phase III trials for an oral GLP-1/GI

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 22:43
Source
Quartr
Simply Wall Street Direct company coverage

Viking Therapeutics (VKTX) Stock Looks Pricey After New Obesity Trial Launch

Viking Therapeutics' stock appears expensive due to a high P/B ratio compared to industry averages, despite a strong five-year return. The launch of its Phase 1 obesity trial for VK3019 supports a broader pipeline, but clinical and regulatory risks persist. The company's valuatio

Tone
Negative 30/100
Event
Regulatory and legal
Published
08 Jul 2026 11:39
Source
Simply Wall Street
Market source Direct company coverage

Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next

Viking Therapeutics has initiated a Phase 1 trial for its new obesity drug VK3019, a dual amylin and calcitonin receptor agonist, broadening its metabolic pipeline alongside its advanced VK2735 program. This development could reshape Viking's investment narrative by adding anothe

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 06:10
Source
Market source
Quartr Direct company coverage

Viking Therapeutics (VKTX) Corporate presentation Summary

Viking Therapeutics (VKTX) presented a summary of its corporate strategy, focusing on novel therapeutics for metabolic and endocrine diseases. Key highlights include the advanced clinical development of VK2735 for obesity, demonstrating significant weight loss in both subcutaneou

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 22:11
Source
Quartr
Quartr Direct company coverage

Viking Therapeutics (VKTX) Q2 2024 earnings summary

Viking Therapeutics (VKTX) reported its Q2 2024 earnings, highlighting positive phase II results for VK2735 in obesity with significant weight reduction and good tolerability. The company also detailed strong cash reserves of $942M, boosted by a public offering, and outlined upco

Tone
Positive 81/100
Event
Earnings
Published
07 Jul 2026 21:10
Source
Quartr
Quartr Direct company coverage

Viking Therapeutics (VKTX) Proxy filing Summary

Viking Therapeutics' proxy filing outlines the agenda for its annual meeting on May 19, 2026, which includes voting on the election of two Class II directors, ratification of CBIZ CPAs P.C. as independent auditors, and an advisory vote on executive compensation. Shareholders regi

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:10
Source
Quartr
Simply Wall Street Direct company coverage

Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation

Viking Therapeutics (VKTX) has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss, adding to its obesity pipeline which includes the late-stage candidate VK2735. The stock has seen significant momentum with a 30-day return of 36.06

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 07:42
Source
Simply Wall Street